PanTera signs agreement with Bayer for the supply of actinium-225

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, today announces the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac) starting in the second half of 2024.

This first agreement with a major drug developer reflects PanTera’s unique position to be a reliable, EU-based supplier of 225Ac from this year onward. In 2024, PanTera will continue to work on increasing access to 225Ac for clinical trial needs, as well as on the development of a large-scale, state-of-the-art production facility to address growing global demand.

Sven Van den Berghe, CEO of PanTera, commented, “PanTera’s emerging ability to start supplying 225Ac this year will allow research and clinical trials in this domain to advance. The combined expertise and technology from SCK CEN and IBA places PanTera in a unique position to become the go-to global supplier of 225Ac for clinical trials and commercial use. PanTera is committed to supporting the pharmaceutical industry by scaling up production to meet the significant global demand for targeted radiopharma-based therapeutics in the fight against cancer.”

For more information: www.pantera-life.com

Related content:

IBA Pioneers Theranostic Advancements, Empowering the Market to Produce Astatine-211

First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma  

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones     

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)       

NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)         

Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal         

Update on Unplanned Outage of the HFR Reactor         

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply         

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals         

How Nuclear Fusion is Revolutionizing Medical Isotope Production         

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes         

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE         

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m